MedTrace Logo

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-03-21

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.

Conditions

  • Obesity and Obesity-related Medical Conditions
  • Obesity and Overweight
  • Obesity Prevention
  • Obesity Recidivism
  • GLP-1
  • Ablation Techniques

Interventions

DEVICE

Gastric Fundal Mucosal Ablation (GFMA)

Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy

Sponsors & Collaborators

  • Dr. Christopher McGowan

    lead OTHER

Principal Investigators

  • Christopher McGowan, MD, MSCR · True You Weight Loss

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06734312 on ClinicalTrials.gov